This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Merck (MRK) Heart Failure Drug Verquvo Gets Approval in Europe
by Zacks Equity Research
Merck (MRK)/Bayer's (BAYRY) vericiguat gets approval for symptomatic chronic heart failure in patients with reduced ejection fraction in Europe.
Biogen (BIIB) Q2 Earnings Top, Aduhelm Early Sales Hit $2M
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.
J&J (JNJ) Beats on Q2 Earnings & Sales, Ups View, Stock Rises
by Zacks Equity Research
J&J (JNJ) beats second-quarter 2021 estimates for both earnings and sales. It raises its financial expectations for the year. It forecasts $2.5 billion in 2021 sales of COVID-19 vaccine.
Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.
Merck (MRK) Gets FDA Nod for Pneumococcal Vaccine Vaxneuvance
by Zacks Equity Research
Merck's (MRK) 15-valent pneumococcal conjugate vaccine, Vaxneuvance includes pneumococcal serotypes, 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
New Strong Sell Stocks for July 19th
by Zacks Equity Research
GPL, MRK, OBLG, POST, and QUMU have been added to the Zacks Rank #5 (Strong Sell) List on July 19, 2021
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $78.02, moving +0.15% from the previous trading session.
Pharma Stock Roundup: NVO & LLY's Small Acquisitions, JNJ's Sunscreens Recall
by Kinjel Shah
Novo Nordisk (NVO) and Eli Lilly (LLY) announce small acquisition deals. J&J (JNJ) recalls some consumer products.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $77.90, marking a +0.36% move from the previous day.
Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data
by Zacks Equity Research
Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.
Seagen (SGEN) Gets Regular Approval, Label Expansion for Padcev
by Zacks Equity Research
Seagen and Astellas' two sBLAs for Padcev get FDA approval for patients with locally advanced or metastatic urothelial cancer. The approval comes one month before the PDUFA date of Aug 17, 2021.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $78.01 in the latest trading session, marking a -0.14% move from the prior day.
Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates
by Kinjel Shah
Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)
Merck's (MRK) Keytruda Gets FDA Nod for Advanced Skin Cancer
by Zacks Equity Research
Merck (MRK) gets approval from the FDA for the label expansion of Keytruda as a monotherapy for treating patients with locally advanced cutaneous squamous cell carcinoma.
Gilead (GILD) Gains 19% YTD: What to Expect in The Second Half?
by Zacks Equity Research
Gilead (GILD) maintains momentum in the year so far on the back of Veklury for the treatment of COVID-19 and the same is expected to continue in the second half.
Merck (MRK) to Withdraw a Gastric Cancer Indication for Keytruda
by Zacks Equity Research
Merck's (MRK) Keytruda is approved under FDA's accelerated pathway for recurrent gastric or gastroesophageal junction adenocarcinoma indication but fails in post-marketing commitment study.
Pharma Stock Roundup: EU Nod to RHHBY, MRK Drugs, FDA and Pipeline Updates
by Kinjel Shah
EU approves Roche's (RHHBY) Enspryng and Merck's (MRK) Keytruda for a new indication. FDA grants EUA to Roche's Actemra for COVID-19.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $77.99, marking a +0.28% move from the previous day.
Alpine (ALPN) Enters Immuno-Oncology Collaboration With Merck
by Zacks Equity Research
Alpine (ALPN) signs a collaboration and supply deal with Merck to evaluate ALPN-202 in combination with the latter's Keytruda for treating various types of cancer.
Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU (Revised)
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study
Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy
by Zacks Equity Research
Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.
Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study
Bristol Myers (BMY) Gets Positive CHMP Opinion for Abecma
by Zacks Equity Research
Bristol Myers (BMY) obtains positive CHMP opinion for cell immunotherapy, Abecma, for multiple myeloma and Opdivo for the indication of gastroesophageal junction cancer.
Mirati's (MRTX) Adagrasib Gets Breakthrough Therapy Status
by Zacks Equity Research
Mirati (MRTX) is developing adagrasib as a potential treatment for patients suffering from non-small cell lung cancer with KRAS mutation. An NDA is expected to be filed in the second half of 2021.
Regeneron (REGN)/Sanofi's Libtayo Approved for Additional Indications
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi win EC approval for Libtayo for skin cancer and lung cancer.